e-Article – 부산대학교 도서관

e-Article

replayBack to search results

searchSearch screen

Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial

Document Type

Article

Author

Molina, Jean-Michel; Rizzardini, Giuliano; Orrell, Catherine; Afani, Alejandro; Calmy, Alexandra; Oka, Shinichi; Hinestrosa, Federico; Kumar, Princy; Tebas, Pablo; Walmsley, Sharon; Grandhi, Anjana; Klopfer, Stephanie; Gendrano, Isaias; Eves, Karen; Correll, Todd A; Fox, Michelle C; Kim, Jason

Source

In The Lancet HIV June 2024 11(6):e369-e379

Subject

Primary Research
Articles

Language

ISSN

2352-3018

Online Access

Full Text (ScienceDirect 종량제) Full Text (Clinical Key) Web of Science JCR 저널정보 Scopus Find it@PNU

이메일